Stelara Biosimilar Now Available in the U.S.
Selarsdi, a biosimilar to Stelara (ustekinumab-aekn) is now available in the U.S. Ustekinumab is U.S. Food and Drug Administration-approved for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic […]